CRC Research Update — August 07, 2026
Today's colorectal cancer research highlights
Archive
A collection of 715 issues
Latest
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
Skip to content
The CRC Digest
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant
Direct visualization system aids stent placement in 39-year-old with malignant obstruction
Skip to content
The CRC Digest
Direct visualization system aids stent placement in 39-year-old with malignant obstruction
A case report describes successful use of a direct visualization device to guide enteral stent placement across a stenotic sigmoid colon tumor in a 39-year-old woman with intestinal obstruction. (Frontiers in Medicine)
This
Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders
Skip to content
The CRC Digest
◇ RESEARCH
Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders
In 20 patients with MSI-H advanced colorectal cancer receiving immunotherapy, metagenomic sequencing and metabolomics revealed distinct gut microbiota and metabolite patterns associated with clinical benefit versus non-benefit, suggesting the microbiome may influence
Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC
This single-arm phase II study investigated whether patients with refractory metastatic colorectal cancer who previously responded to irinotecan could benefit from high-dose irinotecan rechallenge, with dosing adjusted based on
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
Skip to content
The CRC Digest
▸ TREATMENT
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients
National study examines surveillance colonoscopy in Lynch syndrome patients
Skip to content
The CRC Digest
▪ SCREENING
National study examines surveillance colonoscopy in Lynch syndrome patients
A national study of 4,732 Lynch syndrome carriers in the English NHS assessed adherence to surveillance guidelines and aimed to determine the impact of colonoscopic surveillance on colorectal cancer incidence and mortality in
CRC Research Update — August 06, 2026
Today's colorectal cancer research highlights
Shared Decision-Making Framework for CRC Screening Choices
Skip to content
The CRC Digest
Shared Decision-Making Framework for CRC Screening Choices
A review emphasizes the importance of tailoring screening strategies to individual patient risk profiles and using shared decision-making to guide patients through screening choices based on age, family history, comorbidities, and psychosocial factors. (Clinical Colon and Rectal
Early-Onset CRC Among Young Latino Men Linked to Structural Inequities
Skip to content
The CRC Digest
Early-Onset CRC Among Young Latino Men Linked to Structural Inequities
An editorial co-authored by a Latino cancer survivor diagnosed at age 38 examines how molecular epidemiology and structural inequities converge in early-onset colorectal cancer among young Latino men, who face diagnostic delays, lower screening